Payment overview · 2025
General Payments
$349,152.87
242 reported records · 31 companies
Healthcare provider profile · identity verified
Eric Alexander Secemsky, MD, MSC
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BOSTON, MA · NPI 1942535489
Verified facts
What the public records show
CMS Open Payments records show Eric Alexander Secemsky, MD, MSC received $349,152.87 in general payments during 2025 across 242 reported records.
Boston Scientific Corporation accounted for 47.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $164,272.68 | 47.0% | 50 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35,386.36 | 10.1% | 53 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $20,147.44 | 5.8% | 18 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19,983.94 | 5.7% | 12 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $18,796.37 | 5.4% | 9 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $14,825.06 | 4.2% | 20 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $12,303.86 | 3.5% | 7 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $10,080.45 | 2.9% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $8,602.54 | 2.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $6,875.00 | 2.0% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $6,800.00 | 1.9% | 6 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $5,687.28 | 1.6% | 5 | 2025 |
| Inquis Medical, Inc. | Unresolved — no canonical attribution shown | $5,000.00 | 1.4% | 1 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $4,606.34 | 1.3% | 5 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,499.48 | 1.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $4,355.33 | 1.2% | 12 | 2025 |
| Infraredx, Inc. | Unresolved — no canonical attribution shown | $1,500.00 | 0.4% | 2 | 2025 |
| Endovascular Engineering Inc. | Unresolved — no canonical attribution shown | $856.22 | 0.2% | 5 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $750.00 | 0.2% | 1 | 2025 |
| ASAHI INTECC CO., LTD. | Unresolved — no canonical attribution shown | $619.76 | 0.2% | 3 | 2025 |
| MicroVention, Inc. | Unresolved — no canonical attribution shown | $550.00 | 0.2% | 2 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $500.00 | 0.1% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $431.15 | 0.1% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $403.32 | 0.1% | 6 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $400.00 | 0.1% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $361.23 | 0.1% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $357.21 | 0.1% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $145.41 | 0.0% | 3 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $21.69 | 0.0% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $21.24 | 0.0% | 1 | 2025 |
| Nipro Medical Corporation | Unresolved — no canonical attribution shown | $13.51 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $148,237.75 | 83 |
| Acquisitions | $133,510.49 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,140.00 | 12 |
| Travel and Lodging | $20,562.52 | 48 |
| Food and Beverage | $7,402.11 | 96 |
| Honoraria | $5,000.00 | 1 |
| Grant | $300.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $146,076.65 | 16 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $19,282.71 | 9 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $16,710.75 | 11 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $14,825.06 | 20 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $12,732.29 | 39 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTA Normalized: selution slr pta |
Device | CORDIS US CORP. | $12,303.86 | 7 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $10,080.45 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $8,602.54 | 3 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $6,800.00 | 6 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $6,383.79 | 5 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $6,240.00 | 4 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $6,125.00 | 9 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $5,850.00 | 2 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $5,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Aventus Normalized: aventus |
Device | Inquis Medical, Inc. | $5,000.00 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $4,375.00 | 2 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $3,436.69 | 5 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $3,266.88 | 3 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $3,245.62 | 8 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $3,120.00 | 4 | 2025 |
Source payment records
|
|||||
| VIABAHN Endoprosthesis with PROPATEN Bioactive Surface Normalized: viabahn endoprosthesis with propaten bioactive surface |
Device | W. L. Gore & Associates, Inc. | $3,120.00 | 2 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $1,292.49 | 4 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $1,090.32 | 5 | 2025 |
Source payment records
|
|||||
| TENDYNE Normalized: tendyne |
Device | Abbott Laboratories | $1,075.00 | 3 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $972.96 | 4 | 2025 |
Source payment records
|
|||||
| Helo Thrombectomy System Normalized: helo thrombectomy system |
Device | Endovascular Engineering Inc. | $856.22 | 5 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $741.70 | 3 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $701.23 | 3 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $625.00 | 1 | 2025 |
Source payment records
|
|||||
| PV wires Normalized: pv wires |
Device | ASAHI INTECC USA, INC. | $501.57 | 1 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $500.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $448.38 | 6 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $431.15 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $400.00 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $288.66 | 4 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $185.71 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $145.41 | 3 | 2025 |
Source payment records
|
|||||
| Artis icono floor Normalized: artis icono floor |
Device | Siemens Medical Solutions USA, Inc. | $106.34 | 1 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $54.67 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $34.71 | 1 | 2025 |
Source payment records
|
|||||
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | Haemonetics Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| COOK CELECT Normalized: cook celect |
Device | Cook Medical LLC | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Makoto Normalized: makoto |
Device | Nipro Medical Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349,152.87 · 242 records | Boston Scientific Corporation | ANGIO-SEAL, AURYON LASER SYSTEM 100-120 VAC, Artis icono floor, Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Aventus, BioMimics 3D Vascular Stent System, COOK CELECT, Clinical Trial Product, Denali Vena Cava Filter, ELUVIA, ESPRIT, EkoSonic, FFRct, GORE VIABAHN Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, General - Balloon Catheters, General - Therapies, General - Vascular Access, General - Vascular Intervention, HAWKONE, Helo Thrombectomy System, IGT Devices Undivided, IN.PACT ADMIRAL, Indigo System, JETSTREAM SC, LifeVest, Makoto, PV wires, Paradise Ultrasound Renal Denervation System, Peripheral Vascular Undivided, Product in Development, Ranger, RotarexS 6 F x 135 cm, SELUTION SLR PTA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TEG6S HEMOSTASIS SYSTEM, TENDYNE, VIABAHN Endoprosthesis with PROPATEN Bioactive Surface, XIENCE SKYPOINT, ZILVER PTX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error